Navigation Links
MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
Date:7/14/2008

MOUNTAIN VIEW, Calif., July 14 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced it has initiated its Phase 3 clinical program to evaluate MAP0004 as a potential treatment for migraine.

MAP0004 is orally inhaled and self-administered at home using MAP Pharmaceuticals' proprietary Tempo(R) inhaler. In the company's prior Phase 2 efficacy study, MAP0004 provided pain relief in as fast as 10 minutes, with relief sustained through at least 24 hours. The study also demonstrated efficacy trends in treating nausea, photophobia and phonophobia, the other key measurements in treating migraine.

This randomized, double-blind, placebo-controlled Phase 3 trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain relief, and freedom from nausea, photophobia and phonophobia as measured at two hours after dosing. MAP will also evaluate earliest onset of pain relief and sustained relief to 24 and 48 hours. The multi-center efficacy trial will include approximately 850 patients, who will also be followed for 12 months in an open-label study to confirm long-term safety.

"We believe that MAP0004 has the potential to be a first-line therapy for migraine patients," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Based on our initial clinical studies, we believe that MAP0004 offers an alternative to triptans that may provide patients with the benefits of rapid onset and long-lasting pain relief, in an easy-to-use, non-invasive, at-home therapy. In our Phase 2 trials, MAP0004 was well tolerated with no effect on pulmonary function, including in asthmatic subjects."

The therapeutic agent
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., NEW YORK, Nov. 20 Reportlinker...s available in its catalogue. ,, Pipettes &... http://www.reportlinker.com/p0164373/Pipettes--Pi...rce=prnewswire&utm_medium=pr&utm_campaign=...ted as an integral part of any research laboratory...
(Date:11/20/2009)... NATICK, Mass. and LONDON, Nov. 20 /PRNewswire-Fir...BSX ) today announced that it has received 510(k) ...on (FDA) and CE Mark approval to market its WallFl...eatment of malignant esophageal strictures (obstru...le or non-resectable esophageal cancer. ,, (Ph...
(Date:11/20/2009)...MPHIS, Tenn., Nov. 20 ...vision is pleased to announce the signing of a tec...s Department of Defense that may lead to the creat...lutionize the treatment of the limbs of soldiers w...the Defense Advanced Research Projects Agency (DAR...
Breaking Medicine Technology:Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 2Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 3Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 4Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 5Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 6Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 7Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 8Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 9Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 10Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 11Reportlinker Adds Pipettes & Pipettors - A Global Market Perspective 12Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 2Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 3Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent 4Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 2Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 3Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries 4Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients 60088 1Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients 60088 2Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients 60088 3Study shows unsedated colonoscopy for colorectal cancer screening well accepted by patients 60088 4Science at the petascale 3A Roadrunner results unveiled 60085 1Science at the petascale 3A Roadrunner results unveiled 60085 2Science at the petascale 3A Roadrunner results unveiled 60085 3Protein critical for insulin secretion may be contributor to diabetes 60082 1Protein critical for insulin secretion may be contributor to diabetes 60082 2Protein critical for insulin secretion may be contributor to diabetes 60082 3
(Date:11/22/2009)...N, D.C. November 18, 2009 -- When people have mala...which enter the body from the saliva of a mosquito...d blood cells. Inside the blood cells, the parasit...teins on the cell surface that change the physical...iments show that infected red blood cells are stif...
(Date:11/22/2009)... HealthSmart, an innovative healthcare...t has successfully completed a recapitalization wi...o;s other lenders. Silver Point Capital, L.P. is ...ecticut. This recapitalization allows the Company... strategy. , , (PRWEB) N...
(Date:11/21/2009)...ASHINGTON, Nov. 21 DNC ...after the Senate voted to begin full debate of hea...ttp://www.newscom.com/cgi-bin/prnh/20080519/DNCLOG...ic step on the road to enacting health insurance r...enators will now have an opportunity to debate the...
(Date:11/21/2009)... LONDON, November 21, 2009 /PRNewswire-FirstCall/ ...st Test Test Test Test Test Test Test Test Test,Te...st Test Test Test Test,Test Test Test Test Test Te...est More test More test More test More test More t...est More test More test More test More,test More t...
(Date:11/21/2009)... New Haven Dental Group merges their p...ranford, CT. , (PRWEB) No...prised of partners Dr. David Gibson, Dr. Dean Clou...has just merged their growing practice with that o...en Dr. Pickman decided he wanted to retire from de...
Breaking Medicine News(10 mins):Health News:Measuring and modeling blood flow in malaria 2Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Democratic National Committee Chairman Tim Kaine's Statement on the Senate's Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 2Health News:New Haven Dental Group Expands Their Vision 2
...SA, Calif., Oct. 3 CNS Response, Inc.,(OTC Bullet... George C.,Carpenter IV as President. Len Brandt, ... President, will continue as the Company,s chief,e...physical medicine firm that manages occupational h...
... Oct. 3 SearchMedica.com, the,specialty-oriented ...y at,the American Academy of Family Physicians, Sc...experience to allow internal medicine and family,p...rves up the most timely clinical resources to clin...
...IA, Va., Oct. 3 An audio replay is,now available ...sing what,impact the president,s intended veto on ...would have on reducing poverty in America., Catho... poor children, and is asking him to keep his prom...
...iz., Oct. 3 The Well Life Center in Mesa,Arizona,...lthcare,education, announces the launch of its "10...n Tuesday October 9th. Donations benefit The Arizo...o set health goals,that are inline with your value...
...haway, John Legend and Wyclef Jean join Terrence H...p launch the new (2 WEEKS) T-Shirt and ...RANCISCO, Oct. 3 Gap is proud to,introduce its la...bovitz and featuring a diverse cast of,socially-co...
...S Oct. 3, 2007 UT Southwestern Medical Center ha...ulticenter clinical trial that is examining the ef...r brain swelling in children who have suffered sev...e five-year trial, which is being funded by the Na...
Other Medicine News:Health News:CNS Response, Inc. Appoints George C. Carpenter IV to Position of President 2Health News:CNS Response, Inc. Appoints George C. Carpenter IV to Position of President 3Health News:SearchMedica Finds Most Relevant and Now Most Recent Search Results 2Health News:SearchMedica Finds Most Relevant and Now Most Recent Search Results 3Health News:Audio Replay: Catholic Charities USA's Briefing on the Inextricable Link Between a Veto of SCHIP and Poverty in America 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 2Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 3Health News:Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED 4Health News:UT Southwestern investigating hypothermic technique in treating pediatric head injuries 2
...or 14 years -- and works! Baby Gender Mentor Home ...ng technology to attain the earliest gender detect... accuracy. The technique traces the amount of Y ch...ender. Here's how it works: Your baby releases its...
...luorescence in situ hybridization (FISH) assay des...ication in formalin-fixed, paraffin-embedded breas...etermined from the ratio between the number of sig... (red signals) and the number of signals from the ...
...se either the PARI LC PLUS® or PARI LC STAR&re...Maximize aerosol output when the patient inhales a...s using two one-way valves. Baffles allow particle...lt is a high percentage of particles in the respir...
..., ,ACE ensures prompt, effective delivery of aero...le design allows it to be used in a ventilator cir...r resuscitation bag and for routine, oral inhalati...centive spirometer to help teach the patient prope...
Medicine Products: